BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

4-3-dunwoody-3d-shields.png

3D printing community rallies to meet hospitals’ needs in pandemic

April 3, 2020
By Meg Bryant
As health care workers face critical shortages of personal protective equipment (PPE) to deal with the COVID-19 crisis, 3D printing companies, medical device manufacturers and other organizations are stepping up to produce face shields, ventilators and other needed supplies. For its part, Rehovot, Israel-based Stratasys Ltd. has assembled a coalition of more than 150 companies and universities to produce 3D-printed visors and clear plastic face shields. The coalition aims to produce up to 16,000 face shields per week by the end of next week.
Read More
Telehealth illustration

FCC doubles down on existing telehealth pilot, draws raves from advocates

April 3, 2020
By Mark McCarty
The U.S. Federal Communications Commission (FCC) has received funds for another telehealth program in less than a year. An agency statement indicates that the program “would immediately support health care providers” working to thwart the COVID-19 outbreak. This would be achieved in part by supporting purchases of devices and other items needed to provide telehealth, which the Connected Health Initiative said will help drive an overdue overhaul of health care in the U.S.
Read More
Handshake, businessmen holding dollar sign, lightbulb

Med-tech deal and M&A values drop in Q1, significantly down from last year

April 3, 2020
By Karen Carey
A flurry of deal and M&A activity in the med-tech industry during the first quarter of 2020 has not translated into high financials, as many of the transactions are not disclosing terms. While the COVID-19 pandemic rages on, business development activities appear to be slumping in recent weeks, leaving the early part of the year significantly down from prior quarters.
Read More
Scientific data illustration
It’s not FAIR!

Accelerated by COVID-19, science changes will outlast pandemic

April 3, 2020
By Anette Breindl
COVID-19 has disrupted science in the way it has disrupted everything else. In the short term, universities have largely closed shop as a way to maximize social distancing, and lots of science – or at least, lots of bench work – is not getting done.
Read More

Regulatory front for April 3, 2020

April 3, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies.
Read More

Regulatory actions for April 3, 2020

April 3, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Becton Dickinson, Beroni Group, Biogx, Clinical Laserthermia Systems, Leica Biosystems.
Read More

Other news to note for April 3, 2020

April 3, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3M, Aperiomics, Astellas, Beroni Group, Buoy Health, Cigna, Dilon Technologies, Dune Medical Devices, Electrocore, Express Scripts, Foxo Bioscience, Horizon Discover, Insight Enterprises, Insurtech, Life Epigenetics, Mardill Medical, Nexstim, Novocure, Obviohealth, Pancella, Predictive Technology, Pinterest, Stimguard, Wellgistics, Yousurance.
Read More
Venbio team

Recessed entry: $394M funding door open in Venbio model despite hard times

April 3, 2020
By Randy Osborne
Having chalked up three marketed drugs after only nine years in existence, Venbio Partners LLC proved its appeal yet again by closing on about $394 million in a capital raise that included new and existing investors, with a broad range of institutional concerns in the mix.
Read More

Regulatory actions for April 3, 2020

April 3, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cytodyn, Gracell, I-Mab, Iveric, Novan, Revive.
Read More

Other news to note for April 3, 2020

April 3, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: American Cryostem, Aradigm, Brainstorm, Capricor, Celltrion, Emergent, Grifols, GSK, Icagen, Incyte, Innate, Innovax, Ligand, Neurocrine, Novartis, Regenerx, Ridgeback, Savara, Seneca, Siga, Sumitomo, Voltron.
Read More
Previous 1 2 … 495 496 497 498 499 500 501 502 503 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 13, 2026.
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • Skin irritation on hands

    HX-16108 holds promise for treating inflammatory skin diseases

    BioWorld Science
    Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing